We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


HemoCue AB develops, produces, and markets medical diagnostic products for point of care testing (POC) markets. Its p... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Dengue Patients’ Hemoglobin Concentrations Compared by POC and CBC

By LabMedica International staff writers
Posted on 06 Sep 2021
Print article
Image: The HemoCue Hb 201+ System Analyzer has become a standard in hemoglobin point-of-care testing (Photo courtesy of HemoCue AB)
Image: The HemoCue Hb 201+ System Analyzer has become a standard in hemoglobin point-of-care testing (Photo courtesy of HemoCue AB)
Dengue is a mosquito-borne viral infection that is mainly found in tropical and sub-tropical climates. The natural history of dengue has the unique characteristic of plasma leakage that results in hemoconcentration as well as vasculopathy and thrombocytopenia that result in bleeding.

Hematocrit monitoring is a crucial tool to guide management in dengue patients. Microhematocrit adjunct with a complete blood count (CBC) to monitor dengue patients were traditionally performed to decrease the frequency of venipuncture. However, microhematocrit is currently less preferred to the point-of-care hemoglobin monitoring tools to measure red cells in other diseases.

A team of medical scientists at the Ramathibodi Hospital (Bangkok, Thailand) evaluated the relationship between hemoglobin measured by point-of-care hemoglobin (POC-Hb) testing and hematocrit measured by the automated method in adult dengue patients. A total of 44 dengue patients were enrolled. Twenty-nine patients (65.9%) were female, with a median age of 31 years (interquartile range 22–41). Of the enrolled patients, 30 (68.2%), 11 (25.0%), and three (6.8%) were classified as dengue without warning signs, with warning signs, and severe dengue, respectively. Seven patients (15.9%) had hemoconcentration, and five patients (11.3%) had bleeding.

The team measured a CBC by Mindray BC-6800Plus (Mindray, Shenzhen, China) at Ramathibodi Hospital, and Sysmex XN-3000 (Sysmex, Kobe, Japan) at Chakri Naruebodindra Medical Institute. POC-Hb testing was performed on capillary blood and read by the HemoCue Hb 201+ (HemoCue AB, Ängelholm, Sweden). POC-Hb testing was conducted by three physicians who were trained on the use of the device. Hemoconcentration was defined by an increase of ≥20% in hematocrit compared with a convalescent value. A total of 216 pairs of POC-Hb and CBC were evaluated.

The investigators reported that the medians of hemoglobin and hematocrit at dengue presentation were 13.8 g/dL and 41.6%, respectively. The medians of mean corpuscular volume (MCV) and platelets were 87.0 fL and 98,500/mm3, respectively. The team found a significant positive correlation was observed between hemoglobin measured by POC-Hb testing and hematocrit measured by an automated CBC. Bland-Altman analysis between hemoglobin measured by POC-Hb testing and an automated CBC showed a bias of -0.43. Using the cutoff of POC-Hb ≥20% as a criteria for hemoconcentration, the sensitivity and specificity of hemoconcentration detected by POC-Hb device were 71.4% and 100.0%, respectively.

The authors concluded that hemoglobin measurement using POC-Hb testing adjunct with CBC monitoring can be used to monitor plasma leakage as well as hemorrhage in dengue patients. The use of POC-Hb testing is less invasive and requires less blood compared to venipuncture for CBC evaluation. The study was published on August 16, 2021 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Ramathibodi Hospital
HemoCue AB

Gold Supplier
SARS-CoV-2 Antigen Rapid Test
RapiSafe SARS-CoV-2 Antigen Rapid Test (Professional use)
Microbiology IVD System
MALDI Biotyper Sirius One
Gold Supplier
Infectious Diseases Controls
Multichem ID-SeroNeg
Placental Growth Factor ELISA

Print article


Molecular Diagnostics

view channel
Image: New chip could make treating metastatic cancer easier and faster (Photo courtesy of Georgia Institute of Technology)

Simple Blood Test Detection Method Could Revolutionize Cancer Treatment

Cancer spreads via circulating tumor cells (CTCs) that travel through the blood to other organs, and they are nearly impossible to track. When a tumor starts metastasizing, it sheds its cell into the blood.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.